Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News out
Its a shame that all of Matt's "companies" go to $0.00 and stop trading. Any and all money will be lost here. Guaranteed!! Ive been watching this loser do this for years.
Shakeout following positive news. Stay the course ONCS
If its in your strategy to sell oncs and you didnt at higher values, but are choosing to do so now I question your trading methods.
Alternatively, if you are one who is holding for future growth you have to have known that along the way thered be some interesting PPS swings.
Either way, the lack of debt, increase in valuable relationships, addition of core employees, clear business plan, positive results thus far, patents, licences, and propriatary devices, leads me to believe this is a sustainable platform that over time has the potential to grow into a reconized company.
They certainly are following a common roadmap to success.
Good luck
Ive been in ONCS since 2013 on my birthday February 24 and haven't sold a single share. Ive only been accumulating since. Might turn out to be a great present some day : )
Whoever is mad and thinks a young biotech, or any young company for that matter, doesnt need to raise capital is nuts. This is a success for ANY young company. The fact that they have done excellent work so far, enticed investor intrest, and closed this deal is great news! This is a long and bumpy road. For those having an issue today, I suggest you rethink your perspectives. ONCS
Why do you think ONCS presents at so many Investor conferences?? They just locked in what they had been looking for....
Nothing has changed here. This is still a great company, with a great CEO, great clinical trial results, and no debt. Soon to be even more cash heavy. They will continue to advance and produce results that add value. With this added cash I feel even more positive about the future here. ONCS
Its crazy what some folks choose to do with their time. Anyways INBG is building up for a run here. Waiting on news that should spark it
Bruce in very persistent lol He's been here forever trying to keep INBG down. I feel sorry for him
Low 37's have been holding nicely. With only 60 stores and a plan for over 300 I like our chances here. Great growth opportunity for the patient. TCS
Starting to rebound here. Slow trend back up
ICPT is having a great day. Should I put some in ONCS or wait a little?
Id just like to point out that the presentation on the 14th is a Corporate update. That is structure based not trial based. FWIW
resistance vs support
all I'm saying is this will be worth a lot more in the future and how we get there is very important. Straight up is definitely not the way. So if you are able buy more when another opportunity arises.
I still hold my entire position. FYI.. We will check back to .44 Minor support from Dec 27. If that doesn't hold we WILL see mid 30's.
Im just not from the world where stocks only go straight up. Sorry how do I get there. This has to be rare.
I agree the future is bright here don't get me wrong. Very positive events coming. But there is no confirmed support since the run began from .30. This will check back. Believe me
It wasn't a joke
Like Ive always said. Pull backs are healthy and make for a stronger longer more sustained run. Pull backs are NOT bad people..... This type of over bought run is.. Lets go back and regroup. Confirm our support levels and get prepared for a higher high next time up. ONCS
Don't get mad, jus saying. This baby has to pull back to .35 so I can buy more.
At the same time, some members are doubtful that the company's financials measure up to its stock price. While the stock may look fully valued right now, we're looking for an inflection in growth. The pace of revenue growth has been accelerating each year since fiscal 2010. The adjusted EBITDA margin in that time has gone from 9.9% to 12.4%, so as dollars flow into stores more quickly, more of each is going to the bottom line. And although the company is only recently profitable, its solid cash flow (as well as money raised from the IPO) is allowing it to pick up the pace of expansion after several slow years. Another bonus is a recent credit upgrade from Moody's that will lower borrowing costs for any future debt. Cash flow from operations for the quarter ended Aug. 31 was up 150% from the prior year, while free cash flow swung from negative to positive.
Down BUT not out. Great company here with substantial expansion plans. Buy on dips
The market is noticing this company and expansion is a no brainer for this growth company
Room for much continued growth from this level. Projected to open over 150 more stores
The Container Store Beats by .03
The Container Store Group, Inc., Announces Third Quarter Fiscal 2013 Financial ResultsFont size: A | A | A
4:00 PM ET 1/7/14 | BusinessWire
The Container Store Group, Inc. (NYSE:TCS) (the "Company"), today announced financial results for the third quarter and year-to-date ended November 30, 2013.
Kip Tindell, Chairman and Chief Executive Officer, said: "We are pleased with our operating results in the third quarter. Our net sales increase of 7.3% was fueled by our retail business at The Container Store, where sales increased 10.8%. We saw strong performance across new and existing stores as comparable store sales increased 4.7%; our fourteenth consecutive quarter of comparable store sales increases. This performance in combination with our strong product margins and expense management drove adjusted net income per diluted common share of $0.11. These results demonstrate the strength of our differentiated business model, brand awareness, unique employee-first culture and solid execution by the entire team at The Container Store."
Tindell continued: "Our commitment to our Foundation Principles and Conscious Capitalism, our focus on training, communication and solutions-based selling, coupled with strong partnerships with our vendors, results in an unmatched store experience for our customers as they shop the world's most comprehensive and celebrated collection of storage and organization solutions. With 63 stores today, we have a long runway of growth ahead of us as we expand our store base to realize the 300+ store opportunity that we believe exists."
"During the third quarter we reached a significant milestone with our successful initial public offering," Tindell added. "We couldn't have been more thrilled, humbled and honored by the reception we received from the market. By taking this path, we are also able to facilitate broader employee ownership of The Container Store, increasing our ability to operate a business where everyone associated with it thrives. We look forward to continuing to deliver long-term value for all of our stakeholders."
For the third quarter (thirteen weeks) ended November 30, 2013, on a consolidated basis:
-- Net sales increased by 7.3% to $188.3 million from $175.4 million in the third quarter of fiscal 2012. Comparable store sales increased by 4.7%. Net sales in The Container Store retail business were up 10.8% to $163.7 million and Elfa third party sales decreased 11.3% to $24.6 million.
-- Gross margin was 60.0%, an increase of 60 basis points compared to the third quarter of fiscal 2012. Net sales at The Container Store retail business represented 87.0% of consolidated sales in the third quarter fiscal 2013, as compared to 84.2% in third quarter fiscal 2012. Since gross margin percentage is higher in The Container Store retail business, this shift in sales mix led to an improvement in consolidated gross margin.
-- Selling, general and administrative expenses ("SG&A") increased by 8.7% to $88.8 million from $81.7 million in the third quarter of fiscal 2012. SG&A as a percentage of net sales increased 60 basis points primarily due to increases in expenses incurred in preparation for the Initial Public Offering ("IPO"), expenses associated with operating as a public company as well as a timing shift in direct mail expenses.
-- The Company opened two new stores and ended the quarter with 63 stores in 22 states and the District of Columbia. The Company has opened six new stores including the relocation of one undersized, older format store in fiscal 2013.
-- Net interest expense increased to $5.8 million from $5.1 million in the third quarter of fiscal 2012.
View data
U.S. generally accepted accounting principles ("GAAP") net loss Adjusted net income was $5.2 million or $0.11 per diluted common was $9.5 million in the third quarter of fiscal 2013, which share compared to $5.3 million or $0.11 per diluted common share includes $14.6 million of IPO-related stock-based compensation for the third quarter of fiscal 2012, which excludes certain expense, compared to net income of $6.9 million in the third items that we do not consider in the evaluation of ongoing quarter of fiscal 2012. After considering distributions operating performance, including IPO-related expenses, and accumulated to preferred shareholders of $15.6 million and $22.5 distributions accumulated to preferred shareholders in both million in the third quarters of fiscal 2013 and fiscal 2012, periods (see GAAP/Non-GAAP reconciliation table at the end of respectively, net loss per basic and diluted common share was this release). $1.39 in the third quarter of fiscal 2013 compared to $5.32 in the third quarter of fiscal 2012.
-- Adjusted EBITDA increased 7.3% to $24.1 million compared to $22.5 million in the third quarter of fiscal 2012, as calculated in accordance with the Company's Senior Secured Term Loan Facility (see GAAP/Non-GAAP reconciliation table).
For the year to date (thirty-nine weeks) ended November 30, 2013, on a consolidated basis:
-- Net sales increased by 8.6% to $531.7 million from $489.7 million in year to date fiscal 2012. Comparable store sales increased by 3.6%. Sales in The Container Store's retail business were up 11.6% to $466.5 million and Elfa third party sales decreased 9.1% to $65.2 million.
-- Gross margin was 59.0%, an increase of 30 basis points compared to year to date fiscal 2012. Net sales at The Container Store retail business represented 87.7% of consolidated sales in the year to date fiscal 2013, as compared to 85.4% in year to date fiscal 2012. Since gross margin percentage is higher in The Container Store retail business, this shift in sales mix led to an improvement in consolidated gross margin.
-- SG&A increased by 8.8% to $257.9 million from $237.0 million in year to date fiscal 2012. SG&A as a percentage of net sales increased 10 basis points primarily due to increases in expenses associated with the IPO and operating as a public company.
-- Net interest expense increased to $16.9 million from $16.0 million in the corresponding period of fiscal 2012.
View data
GAAP net loss was $10.2 million, which includes $14.6 million of Adjusted net income was $5.7 million or $0.12 per diluted common IPO-related stock based compensation expense, compared to a GAAP share compared to $4.2 million or $0.09 per diluted common share net loss of $2.2 million in the corresponding period of fiscal in the corresponding period of fiscal 2012, which excludes 2012. After considering distributions accumulated to preferred certain items that we do not consider in the evaluation of shareholders of $59.7 million and $65.4 million in the first ongoing operating performance, including IPO-related expenses, thirty-nine weeks of fiscal 2013 and fiscal 2012, respectively, and distributions accumulated to preferred shareholders in both net loss per basic and diluted common share was $8.78 compared periods (see GAAP/Non-GAAP reconciliation table). to $23.08 in the corresponding period of fiscal 2012.
-- Adjusted EBITDA increased 8.0% to $56.8 million compared to $52.6 million in the third quarter of fiscal 2012, as calculated in accordance with the Company's Senior Secured Term Loan Facility (see GAAP/Non-GAAP reconciliation table).
Balance sheet highlights as of November 30, 2013:
-- Cash: $10.8 million
-- Total debt: $368.5 million (after giving effect to pay-down of $31.0 million with net IPO proceeds to the Company)
-- Total liquidity (cash plus availability on revolving credit facilities of $68.1 million): $78.9 million
Outlook
For fiscal 2013, consolidated net sales are expected to be $754 million based on opening six new stores, inclusive of one store relocation, and an increase in comparable store sales of 3.4%. Adjusted net income, which excludes certain items that we do not consider in our evaluation of ongoing operating performance and distributions accumulated to preferred shareholders, is expected to be $0.40 per diluted common share based on estimated adjusted diluted common shares outstanding of 48.8 million.
Thanks lasers
can someone post the trades from today. Buys vs sells? thanks
Are u also considering the 20 mil possible shares at .36 that could but probably WONT be exercised?
can someone post the trades from today. Buys vs sells? thanks
Not sure if this was posted...
Here Is What Can Propel MerckFont size: A | A | A
1:11 PM ET 12/19/13 | TREFIS
Sooner or later, Merck (NYSE:MRK) will need to step up its efforts to mitigate the impact of loss of exclusivity of certain key drugs and adverse currency movements on its revenue growth. The recent quarters have unveiled a problem that is impacting the whole pharmaceutical industry. The R&D productivity has declined and the ability of the new drugs in pipeline to replace previous blockbusters is under doubt. Under these circumstances, where should Merck be focusing? The market for oncology, infectious diseases and diabetes is growing due to an increasing patient pool. This presents strong growth opportunity for Merck and other pharmaceutical companies. In addition, there is an opportunity to expand in Asia Pacific and Latin American regions which accounted for just about 10% of Merck’s revenue in 2012.
Our current price estimate for Merck stands at $52, implying a slight premium to the market price
See our complete analysis for Merck
Stepping Up Vaccination Efforts
Merck needs to make efforts to ensure that its HPV (human papillomavirus) vaccine Gardasil continues its topline growth. Japanese governments decision to suspend proactive recommendation of HPV vaccine has impacted the drug’s sales in the recent quarter. While this raises some concern, there is another issue that the company needs to tackle domestically in the U.S. The vaccination rates have been relatively low for Gardasil and other HPV vaccines. According to The Journal of American Medical Association (JAMA), only about 54% of girls received at least one dose of an HPV vaccine in 2012, with just 33% receiving the full course of 3 shots. In comparison, about 85% of teens received vaccination for tetanus, diphtheria and whooping cough during the same period. This essentially indicates that Garadasil is missing out on a lot of potential customers, and could effectively increase its sales by another 60% if steps were taken to increase the awareness about the necessity of the vaccine.
We expect Gardasil’s sales to exceed $1.8 billion in 2013, up 50% from $1.2 billion in 2009. If HPV vaccination rates were to increase to the levels of other vaccines, the revenues from Gardasil could jump to close to $3 billion in the next few years. This vaccine accounts for roughly 15%-20% of Merck’s anti-infective division’s revenues (reflected as Legacy Pharma), which in turn constitutes roughly 30% to the company’s value according to our estimates. This implies that 5% of Merck’s value can be attributed to Gardasil based on our current revenue projections. The scenario discussed above could add $1 billion in incremental revenues leading to a some upside to Merck’s stock. The upside will be relatively small because Merck is a large diversified pharmaceutical company and no single drug accounts for a substantial portion of its revenues.
Expansion In Oncology
The FDA had granted breakthrough status to Merck’s lambrolizumab in April 2013, which is an investigational PD-1 specific monoclonal antibody for the treatment of advanced malignancy. The drug essentially enables a patients immune system to detect cancerous cells that are otherwise extremely hard to identify. T cells can then target and kill these exposed tumor cells. The company can leverage this success to tap into the growing oncology (cancer therapeutics) market, assuming that the drug passes phase 3 trials and is approved by the FDA for commercial sale. The opportunity in oncology comes from the fact that global incidence of Cancer is likely to increase from about 12.7 million in 2008 to 21.3 million in 2030. In addition, the number of deaths are likely to show a similar growth trajectory as depicted in the chart below. Cancer is a not a single disease, it has in fact more than 200 types and thousands of subtypes affecting more than 60 organs. That gives an opportunity for the company to develop novel therapies and capture niche markets
Cancer Incidence, Source: J&J Investor Presentation
Staying Resilient In Diabetes Market
Although Merck is facing some competition from Johnson & Johnson in diabetes market due to latter’s launch of Invokana, it still has a dominant position in the U.S. Besides defending this position, the company needs to address international diabetes market where most of the growth potential lies. Increasing urbanization in some of the biggest Asian economies is resulting in an higher incidence of lifestyle related diseases including diabetes. While there are roughly 26 million people that suffer from this condition in the U.S., Chinas problem is even worse. A report suggests that 11.6% of Chinese adults have diabetes and around 40% of adults between the age of 18 and 29 are on the verge of developing it. That puts Chinas diabetes patient count at 114 million individuals, and this figure is likely to go higher. According to IMS health, Chinas diabetes market is expected to grow 20% annually and reach $3.2 billion by 2016.
Mercks type 2 diabetes treatment drugs Januvia and Janumet have witnessed strong volume growth in international regions, but their sales in the U.S. have suffered recently due to competition from J&J’s Invokana. The overall market has been stable which implies that Invokana is taking away some volume from Januvia, which is one of Mercks biggest drugs with over $4 billion in sales in 2012. While the trend may continue in the near term, the company will need to take steps to ensure that Januvia gets back on growth track. We currently account for Januvias revenues under Alimentary & Metabolism drugs division, which constitutes roughly 15% to our price estimate for Merck. Januvias importance can be gauged from the fact that the exclusion of the drugs sales from Mercks revenue forecast leads to downside of about 5-10% to our price estimate. Thats a lot of value for a single drug in a diversified company like Merck.
Im also happy to see that [SMARTMONEY] has posted on this board 9 times. Today, being one of them. It is always good to see that ONCS
Id say we held up nicely today. Held most gains. Decent base at old 52 week high. Trading great
Awesome ride!! Well it touched .38. Anybody kno the close?
Sabai, if u don't mind me asking. How much does a 430 spider go for in Switzerland? BTW 5 min to close at .38 ONCS
TADF coming in for landing